Interaction Checker

Apps

Download from the AppStore

Download from Google Play

Interaction Checker
About Us
Mission Statement Meet the Team Steering Committee
Interaction Checkers
Interaction Checker Español Checker Português Checker Interaction Checker Lite View All Checker
Prescribing Resources Videos Site News
Contact Us
Feedback Form Suggest a Drug
Support Us
Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more
Start a new interaction query Switch to Table View

Generate a personalised report in PDF format

Do Not Coadminister

Bictegravir/ Emtricitabine/Tenofovir alafenamide (BIC/FTC/TAF)

Oxcarbazepine

Quality of Evidence: Very Low

Summary:

Coadministration is not recommended. Oxacarbazepine is an inducer and is expected to decrease both tenofovir alafenamide and bictegravir exposures, which may result in loss of therapeutic effect and development of resistance. Alternative anticonvulsants should be considered.

Description:

Co-administration is not recommended. The interaction has not been studied with any of the components of Biktarvy. Co-administration may decrease bictegravir and tenofovir alafenamide plasma concentrations due to induction of CYP3A, UGT1A1, and P-gp.
Biktarvy Summary of Product Characteristics, Gilead Sciences Ltd, June 2019.

Coadministration may decrease concentrations of bictegravir and tenofovir alafenamide. Coadministration with alternative anticonvulsants should be considered.
Biktarvy Prescribing Information, Gilead Sciences Inc, August 2019.

SPONSORS
EDITORIAL SPONSORS
Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
healthline-best-HIV-and-AIDS-apps-of-2019
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016
Cookie Policy Privacy Statement Terms & Conditions

Copyright © 2024 The University of Liverpool. All rights reserved.